Sugi Predict

Sugi Predict / Compounds / SCHEMBL139273

SCHEMBL139273

SCHEMBL139273

COC(=O)c1cc(Br)nc(-c2ccc(OC)nc2)c1N

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MKNK1 Q9BUB5 1/20 0.45
▸ MKNK2 Q9HBH9 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ PIK3CA P42336 3/20 0.42
▸ HDAC6 Q9UBN7 2/20 0.42
▸ KCNH2 Q12809 1/20 0.40
▸ RCE1 Q9Y256 1/20 0.40
▸ PIK3CG P48736 2/20 0.40
▸ PRKAG1 P54619 1/20 0.40
▸ PRKAA1 Q13131 1/20 0.40
▸ PRKAB1 Q9Y478 1/20 0.40
▸ PIK3CD O00329 1/20 0.40
▸ PIP5K1C O60331 1/20 0.40
▸ PIK3CB P42338 1/20 0.40
▸ PI4KA P42356 1/20 0.40
▸ PI4KB Q9UBF8 1/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ MTOR P42345 2/20 0.40
▸ HDAC3 O15379 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL109836 0.88 ALOX5AP (0.40) L3MBTL1HDAC6MEN1KMT2AATR
SCHEMBL141016 0.84 PLA2G2A (0.55) MKNK1MKNK2RCE1ATRKDM4E
SCHEMBL109071 0.82 CA12 (0.42) L3MBTL1MEN1KMT2AMAPK1KDM4E
SCHEMBL139223 0.82 MAPT (0.47) L3MBTL1MEN1KMT2AMAPK1KDM4E
SCHEMBL139274 0.81 L3MBTL1 (0.41) L3MBTL1MEN1KMT2ANNMTKDM4E
SCHEMBL23958640 0.81 LMNA (0.49) L3MBTL1MAPK1KDM4EALDH1A1
SCHEMBL110319 0.81 MAPT (0.48) L3MBTL1MEN1KMT2AKDM4EALDH1A1
SCHEMBL110248 0.79 KDM4E (0.42) L3MBTL1MEN1KMT2AKDM4EALDH1A1
SCHEMBL110183 0.79 ATR (0.46) HDAC6MEN1KMT2AMTORATR
SCHEMBL110399 0.79 KMO (0.45) L3MBTL1RCE1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 — — US disclosed
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 — — US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 — — EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 — — US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 — — US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 — — EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 MKNK1 233/4885MKNK2 155/4885L3MBTL1 2220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.